STOCK TITAN

Vanguard discloses zero Pulmonx holdings after internal realignment (NASDAQ: LUNG)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Vanguard Group filed an amended Schedule 13G/A reporting that it beneficially owns 0 shares of Pulmonx Corp Common Stock (CUSIP 745848101). The filing states this follows an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, which resulted in certain Vanguard subsidiaries reporting ownership separately. The filing lists the filer address as 100 Vanguard Blvd., Malvern, PA and is signed by Ashley Grim on 03/27/2026.

Positive

  • None.

Negative

  • None.

Insights

Vanguard reports no beneficial ownership in Pulmonx after an internal reorganization.

The filing documents an internal realignment dated January 12, 2026, citing SEC Release No. 34-39538, and states Amount beneficially owned: 0 and Percent of class: 0%.

Cash-flow treatment and any holdings now reported by specific Vanguard subsidiaries are not listed in this excerpt; subsequent filings by those separate entities could show redistributed positions.






745848101

(CUSIP Number)
03/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

Does The Vanguard Group own Pulmonx (LUNG) shares according to this filing?

No. The filing states The Vanguard Group beneficially owns 0 shares of Pulmonx Common Stock. The amendment attributes this change to an internal realignment effective January 12, 2026, after which certain subsidiaries report separately.

Why does Vanguard report zero ownership in this Schedule 13G/A?

Because of an internal realignment on January 12, 2026, Vanguard states certain subsidiaries will report beneficial ownership separately. The filing cites SEC Release No. 34-39538 as the basis for disaggregation.

Who signed the Schedule 13G/A for The Vanguard Group reporting Pulmonx ownership?

The form is signed by Ashley Grim, Head of Global Fund Administration. The signature date is 03/27/2026, as shown in the filing excerpt.

What address is listed for The Vanguard Group on this filing?

The filing lists The Vanguard Group's principal business office as 100 Vanguard Blvd., Malvern, PA, 19355. The issuer's principal executive office is listed separately as 700 Chesapeake Drive, Redwood City, CA, 94063.

Does this filing show holdings by Vanguard subsidiaries after the realignment?

No. The amendment explains subsidiaries will report separately but does not list any subsidiary holdings in this excerpt. Separate filings by those subsidiaries would show any redistributed positions.
Pulmonx Corp

NASDAQ:LUNG

View LUNG Stock Overview

LUNG Rankings

LUNG Latest News

LUNG Latest SEC Filings

LUNG Stock Data

52.37M
37.47M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
REDWOOD CITY